Sermorelin and GH-Producing Cells: A Research Overview

Sermorelin is the synthetic 29-amino acid N-terminal fragment of endogenous GHRH, representing the minimum active sequence for full GHRH receptor binding and activation. It is the most physiologically direct approach to GH axis stimulation among synthetic GH secretagogues.

Somatotroph Activation Mechanism

GHRH-R is a class B GPCR on pituitary somatotrophs. Sermorelin binding activates adenylyl cyclase → cAMP → PKA, producing two distinct effects:

1. Acute: PKA phosphorylates voltage-gated calcium channels → intracellular calcium rise → immediate GH exocytosis

2. Chronic: PKA activates CREB → GH gene transcription → increased somatotroph secretory capacity

This chronic transcriptional effect means long-term Sermorelin treatment can restore somatotroph mass and secretory competence in aging — a physiological benefit not achievable with exogenous GH, which suppresses the same system through negative feedback.

Clinical Evidence in GH Deficiency

Khorram O et al. (*Journal of Clinical Endocrinology & Metabolism*, 1997) administered sermorelin at 30 mcg/kg daily for 6 months to older adults (mean age 70) with documented GH deficiency:

• Mean IGF-1 increased from 121 ± 14 to 202 ± 21 ng/mL (p<0.001)
• Lean body mass increased 2.4% by DEXA (p<0.05)
• Fat mass decreased 1.8% (p<0.05)
• Slow-wave sleep duration increased 23% by polysomnography

Crucially, no pituitary desensitisation was observed over 6 months — consistent with sermorelin's physiological pulsatile mechanism preserving GHRH-R sensitivity.

Contrast With CJC-1295

CJC-1295 (no DAC) has 4-amino-acid substitutions that block DPP-IV cleavage, extending half-life from sermorelin's 10-12 minutes to ~30 minutes. This enables broader GH pulses (~90-120 min vs ~60-75 min for sermorelin) per injection. For most research applications, the two are mechanistically interchangeable, with CJC-1295 preferred for convenience.

CJC-1295 with DAC, by contrast, produces 8-10 days of continuous GHRH-R activation and is pharmacologically distinct from both sermorelin and CJC-1295 without DAC.

Combination With GHRPs

When co-administered with Ipamorelin or GHRP-2, sermorelin's GH-releasing effect is amplified 3-5× through complementary receptor mechanisms. Walker RF (*Current Opinion in Investigational Drugs*, 2006) concluded that GHRH + GHRP co-administration produces GH pulses far exceeding either agent alone.

Sermorelin's current US regulatory status does not permit adult compounding. This content is for research and education only.